Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of the Belgian firm’s recent history including expansion into the US, how a USD ten million injection of Series A financing could catapult Fluidda to the next level, and why COVID-19 should be the watershed moment for innovation in the respiratory space.
What we see clearly with COVID is the need for better technology and approaches to respiratory disease
